mgi-114
Small moleculeexperimental
Clinical trial activity
19 trials · 17 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
17
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 1998 (NCT00003390)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Kidney Neoplasms · Phase 2
- Leukemia · Phase 1
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Melanoma · Phase 2
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 3
- Prostatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
- Thyroid Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle.
Chemistry & pharmacology
Loading structure…
SMILES
CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1- Mol. weight
- 246.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL118218 ↗
Also known as
- 6-hydroxymethylacylfulvene
- 6-hydroxymethylacylfulvene
- 6-hydroxymethylacylfulvene
- 6-hydroxymethylacylfulvene
- 6-hydroxymethylacylfulvene
- 6-hydroxymethylacylfulvene
- 6-hydroxymethylacylfulvene
- 6-(hydroxymethyl)acylfulvene
- hmaf
- hmaf
- hmaf cpd
- irofulven
- irofulven
- irofulven
- irofulven
- irofulven
- irofulven
- irofulven
- (-)-irofulven
- mgi 114
- mgi-114
- mgi-114
- mgi-114
- mgi-114
- mgi.114
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00124527 | Phase 2 | Mar 1, 2005 | Eisai |
| NCT00124566 | Phase 2 | Jun 1, 2004 | Eisai |
| NCT00374660 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2003 | Eisai |
| NCT00062257 | Phase 2 | Jun 1, 2003 | Cancer Therapeutics Research Group, City University of Hong Kong, National Cancer Institute (NCI) |
| NCT00053365 | Phase 2 | Jun 1, 2003 | Gynecologic Oncology Group, National Cancer Institute (NCI) |
| NCT00012038 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2001 | National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT00005031 | Phase 2 | Aug 1, 2000 | Gynecologic Oncology Group, National Cancer Institute (NCI), Temple University |
| NCT00005070 | Phase 2 | Jan 1, 2000 | Cornell University, National Cancer Institute (NCI) |
| NCT00033735 | Phase 3 | Jan 1, 2000 | Eisai |
| NCT00005968 | Phase 2 | Nov 1, 1999 | National Cancer Institute (NCI), University of Colorado, Denver |
| NCT00003997 | Phase 1 | Jul 1, 1999 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00003796 | Phase 2 | May 1, 1999 | National Cancer Institute (NCI), University of Texas, San Antonio |
| NCT00003786 | Phase 2 | Apr 1, 1999 | National Cancer Institute (NCI), University of Chicago |
| NCT00003760 | Phase 2 | Nov 1, 1998 | Merck, National Cancer Institute (NCI), The University of Texas, Dallas, University of Texas at Houston, University of Texas, San Antonio |
| NCT00003666 | Phase 2 | Nov 1, 1998 | Medical University of South Carolina, National Cancer Institute (NCI) |
| NCT00019552 | Phase 2 | Sep 1, 1998 | National Cancer Institute (NCI) |
| NCT00003370 | Phase 1 | Aug 1, 1998 | National Cancer Institute (NCI), University of Mississippi |
| NCT00003441 | Phase 2 | Aug 1, 1998 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00003390 | Phase 2 | Jun 1, 1998 | Cornell University, National Cancer Institute (NCI), Sanofi |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (17)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 15 | 7 | 2 | 1998 |
| Eisai | For profit | 4 | 4 | 2 | 2000 |
| University of Texas at Houston | Academic/Hospital | 3 | 1 | 2 | 1998 |
| Cornell University | Academic/Hospital | 2 | 2 | 1 | 1998 |
| Gynecologic Oncology Group | Academic/Hospital | 2 | 1 | 1 | 2000 |
| University of Texas, San Antonio | Academic/Hospital | 2 | 1 | 1 | 1998 |
| Cancer Therapeutics Research Group | Academic/Hospital | 1 | 1 | 1 | 2003 |
| City University of Hong Kong | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Medical University of South Carolina | Academic/Hospital | 1 | 0 | 1 | 1998 |
| Merck | For profit | 1 | 0 | 1 | 1998 |
| Sanofi | For profit | 1 | 0 | 1 | 1998 |
| Temple University | Academic/Hospital | 1 | 0 | 1 | 2000 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 1998 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 1999 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 1999 |
| University of Mississippi | Academic/Hospital | 1 | 0 | 1 | 1998 |
17 organizations
Page 1 / 1